Elizabeth J Perlman

  • 12322 Citations
1987 …2019
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Pediatric Pathology

Wilms tumors, germ cell tumors, genitourinary development

Certifications and Licenses

Pediatric Pathology
Anatomic Pathology

Training Experience

1990Fellowship, Johns Hopkins Hospital
1990Residency, Johns Hopkins Hospital

Education/Academic qualification

MD, Johns Hopkins University

… → 1984

Research interests

  • Pathology

Fingerprint Dive into the research topics where Elizabeth J Perlman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Wilms Tumor Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Kidney Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Germ Cell and Embryonal Neoplasms Medicine & Life Sciences
Histology Medicine & Life Sciences
Comparative Genomic Hybridization Medicine & Life Sciences
Clear Cell Sarcoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2012 2019

Research Output 1987 2019

1 Citation (Scopus)

Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology wilms tumor: A Children's Oncology Group AREN0532 and AREN0533 study report

behalf of the AREN0532 and AREN0533 study committees., Jan 1 2019, In : Journal of Clinical Oncology. 37, 30, p. 2769-2777 9 p.

Research output: Contribution to journalArticle

Wilms Tumor
Loss of Heterozygosity
Disease-Free Survival
3 Citations (Scopus)

Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5)

Seibel, N. L., Chi, Y. Y., Perlman, E. J., Tian, J., Sun, J., Anderson, J. R., Ritchey, M. L., Thomas, P. R., Miser, J., Kalapurakal, J. A., Grundy, P. E. & Green, D. M., Jan 2019, In : Pediatric Blood and Cancer. 66, 1, e27450.

Research output: Contribution to journalArticle

Clear Cell Sarcoma
Disease-Free Survival
1 Citation (Scopus)

Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor

Ortiz, M. V., Ahmed, S., Burns, M., Henssen, A. G., Hollmann, T. J., MacArthur, I., Gunasekera, S., Gaewsky, L., Bradwin, G., Ryan, J., Letai, A., He, Y., Naranjo, A., Chi, Y. Y., LaQuaglia, M., Heaton, T., Cifani, P., Dome, J. S., Gadd, S., Perlman, E. & 3 others, Mullen, E., Steen, H. & Kentsis, A., Aug 8 2019, In : JCI Insight. 4, 15, e127098.

Research output: Contribution to journalArticle

Open Access
Wilms Tumor
Drug Therapy
3 Citations (Scopus)

Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study

AREN0321 Study Committee, Sep 2019, In : European Journal of Cancer. 118, p. 58-66 9 p.

Research output: Contribution to journalArticle

Wilms Tumor
Disease-Free Survival
3 Citations (Scopus)

A unique subset of low-risk wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A children’s oncology group study

Armstrong, A. E., Gadd, S., Huff, V., Gerhard, D. S., Dome, J. S. & Perlman, E. J., Dec 2018, In : PloS one. 13, 12, e0208936.

Research output: Contribution to journalArticle

Wilms Tumor
Set theory